Table 2.
Ezetimibe Versus Placebo: Longitudinal Full Liver Fat Mapping Using MRI PDFF and MRS With Colocalized MRI Measurements
| 2A | Ezetimibe (n = 23) |
Placebo (n = 22) |
Difference | ||||
|---|---|---|---|---|---|---|---|
| Liver Segments | Baseline | Posttreatment | P Value | Baseline | Posttreatment | P Value | (P Value) |
| 1 | 15.1 (8.6) | 11.9 (6.8) | 0.0249 | 18.1 (7.5) | 16.5 (5.9) | 0.2298 | −1.5 (0.4341) |
| 2 | 13.9 (8.3) | 10.8 (6.5) | 0.0336 | 17.3 (7.9) | 15.7 (5.9) | 0.2458 | −1.3 (0.4913) |
| 3 | 14.8 (9.1) | 11.9 (7.8) | 0.0585 | 18.2 (7.7) | 16.5 (6.1) | 0.2803 | −1.2 (0.5832) |
| 4a | 15.6 (8.8) | 11.9 (6.9) | 0.0044 | 18.6 (7.8) | 16.7 (5.8) | 0.1677 | −1.8 (0.3028) |
| 4b | 15.1 (8.9) | 12.0 (7.3) | 0.0326 | 18.6 (7.7) | 16.3 (6.6) | 0.0712 | −0.8 (0.6646) |
| 5 | 15.0 (9.7) | 11.3 (7.5) | 0.0148 | 18.9 (9.3) | 16.5 (7.1) | 0.1119 | −1.3 (0.5149) |
| 6 | 14.8 (8.9) | 11.2 (7.1) | 0.0170 | 18.3 (8.6) | 15.9 (6.3) | 0.1232 | −1.2 (0.5462) |
| 7 | 15.2 (8.6) | 11.5 (6.6) | 0.0067 | 19.1 (8.8) | 16.7 (6.5) | 0.1526 | −1.4 (0.4951) |
| 8 | 15.4 (8.6) | 11.7 (6.8) | 0.0098 | 19.2 (8.6) | 17.0 (6.5) | 0.1562 | −1.5 (0.4547) |
| MRI PDFF (%) average | 15.0 (8.7) | 11.6 (6.9) | 0.0158 | 18.5 (8.0) | 16.4 (6.1) | 0.1512 | −1.3 (0.4839) |
| 2B | Ezetimibe (n = 19) | Placebo (n = 21) | Difference | ||||
|---|---|---|---|---|---|---|---|
| Baseline | Posttreatment | P Value | Baseline | Posttreatment | P Value | (P Value) | |
| MRS (%) | 16.4 (8.6) | 13.1 (7.0) | 0.0178 | 18.5 (7.8) | 17.0 (6.2) | 0.3024 | −1.9 (0.3345) |
| 2C | Ezetimibe (n = 19) | Placebo (n = 21) | Difference | ||||
|---|---|---|---|---|---|---|---|
| MRI-level | Baseline | Posttreatment | P Value | Baseline | Posttreatment | P Value | (P Value) |
| MRI-s | 15.8 (8.8) | 12.3 (6.9) | 0.0142 | 18.5 (8.2) | 16.6 (6.9) | 0.1828 | −1.6 (0.3944) |
| MRI-m | 15.7 (8.9) | 12.3 (7.2) | 0.0163 | 18.4 (8.3) | 16.4 (6.7) | 0.1549 | −1.5 (0.4046) |
| MRI-i | 15.5 (9.1) | 12.1 (7.0) | 0.0257 | 17.9 (8.4) | 16.2 (6.6) | 0.2175 | −1.7 (0.3870) |
| MRI average | 15.7 (8.9) | 12.2 (7.0) | 0.0173 | 18.2 (8.3) | 16.4 (6.7) | 0.1800 | −1.6 (0.3906) |
| Pearson r | 0.992 P < 0.0001 | 0.994 P < 0.0001 | 0.990 P < 0.0001 | 0.982 P < 0.0001 | |||
| Spearman ρ | 0.989 P < 0.0001 | 0.982 P < 0.0001 | 0.977 P < 0.0001 | 0.952 P < 0.0001 | |||
Data are expressed as means (SD) or mean difference with P values in parentheses. Associated P values are from t test. Correlation coefficient expressed as Pearson's r and nonparametric Spearman's rho ρ with corresponding P value. P values shown in bold are statistically significant.
In 2A, MRI PDFFs measured in all nine liver segments were used to calculate segmental and overall fat fraction averages at baseline and posttreatment between the ezetimibe and placebo groups. In 2B, longitudinal changes in MRS measurements are shown. In 2C, internal cross-validation is shown between MRI-PDFF and MRS-PDFF and their correlations.
Abbreviations: MRI-PDFF, magnetic resonance imaging proton density-fat fraction; MRS, magnetic resonance spectroscopy; MRI-s, magnetic resonance imaging superior; MRI-m, magnetic resonance imaging middle; MRI-i, magnetic resonance imaging inferior.